SEC ownership of DELCATH SYSTEMS, INC.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000872912.

Comparable stake leader

Rosalind Advisors, Inc.

Disclosed value leader

Rosalind Advisors, Inc.

Comparable rows

50/50

Latest evidence

31 Mar 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
Rosalind Advisors, Inc.
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
31 Mar 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0000872912
Issuer location
Queensbury, NY

Ownership snapshot

Top shareholders of DELCATH SYSTEMS, INC. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Rosalind Advisors, Inc.
Disclosed value leader
Rosalind Advisors, Inc.
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G 3/4/5 13F Lead comparable stake: 9.9% 13D/G row: Rosalind Advisors, Inc. Showing 1-8 of 50 holder rows.

Quick read

Rosalind Advisors, Inc. leads the comparable SEC ownership view at 9.9%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Rosalind Advisors, Inc.'s linked filing trail.
Comparable ownership Top 5
Rosalind Advisors, Inc. 9.9%
BlackRock, Inc. 5%
Vivo Opportunity Fund Holdings, L.P. 2.2%
VANGUARD CAPITAL MANAGEMENT LLC 2%
Propel Bio Management, LLC 1.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Rosalind Advisors, Inc.
13D/G 3/4/5 13F
Director · Company
9.9%
$70,022,327
6,719,993 shares
+$468,900 31 Dec 2025
BlackRock, Inc.
13D/G 13F
Company
5%
$18,845,008
1,753,024 shares
$0 30 Sep 2025
Vivo Opportunity Fund Holdings, L.P.
13D/G
2.2%
$9,002,340
750,195 shares
$0 31 Mar 2025
VANGUARD CAPITAL MANAGEMENT LLC
13F
Company
13F
2%
$12,335,793
1,329,288 shares
31 Mar 2026
Propel Bio Management, LLC
13F
Company
13F
1.4%
$9,159,490
979,698 shares
31 Mar 2026
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
13F
1%
$6,423,891
692,031 shares
31 Mar 2026
STATE STREET CORP
13F
Company
13F
0.98%
$6,165,892
664,428 shares
31 Mar 2026
Private Wealth Advisors, LLC
13F
Company
13F
0.87%
$5,489,343
591,524 shares
31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to buying over the last 12 months. Net value: +$287,368.

Buys
$287,368
Insiders: 3
Sells
$0
Insiders: 0
Net
+$287,368
Shares: +32,619
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 32,619 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 16,733 0 $150,328 $0 +$150,328
6-9 15,886 0 $137,041 $0 +$137,041
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-17 of 17 reporting-owner rows connected to DELCATH SYSTEMS, INC.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
17
Largest Forms 3/4/5 holder
Gil Aharon
Net 12M change
+$287,368
Latest report
13 May 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Gil Aharon Director $47,360,631 Mixed 13 May 2026
Steven A. J. Salamon Director $47,360,631 Mixed 13 May 2026
Rosalind Advisors, Inc. Director $47,360,631 Mixed 05 May 2025
Gerard J. Michel CHIEF EXECUTIVE OFFICER, Director $3,063,324 +$198,358 +6.9% Filing P/S 02 Mar 2026
Vojo Vukovic Chief Medical Officer $807,255 Mixed 17 Feb 2026
Sandra Pennell Chief Financial Officer $696,242 +$50,018 +7.7% Filing P/S 06 Mar 2026
John Richard Sylvester Director $132,781 +$38,992 +42% Filing P/S 13 May 2026
John Purpura Chief Operating Officer $124,578 Mixed 08 Feb 2023
Martha S. Rook Chief Operating Officer Mixed 17 Feb 2026
Christine Padula Interim Principal Accounting Officer Mixed 01 Sep 2021
Kevin Muir Gm Interventional Oncology Mixed 17 Feb 2026
David L. Hoffman Gen'l Counsel, Cco & Secy Mixed 17 Feb 2026
Elizabeth Czerepak Director Mixed 13 May 2026
Anthony Dias Vp Finance Mixed 08 Feb 2023
Roger G. Stoll PhD Director Mixed 23 May 2024
Johnny John Svp Clinical Dev & Med Affairs Mixed 08 Feb 2023
Bridget A. Martell Director Mixed 13 May 2026

Recent insider transactions for DELCATH SYSTEMS, INC.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
John Richard Sylvester DCTH Stock Option (right to buy) Award 22,500 22,500 13 May 2026 Direct
Bridget A. Martell DCTH Stock Option (right to buy) Award 22,500 22,500 13 May 2026 Direct
Elizabeth Czerepak DCTH Stock Option (right to buy) Award 22,500 22,500 13 May 2026 Direct
Steven A. J. Salamon DCTH Stock Option (right to buy) Award 22,500 22,500 13 May 2026 Direct
Gil Aharon DCTH Stock Option (right to buy) Award 22,500 22,500 13 May 2026 Direct
Sandra Pennell DCTH Common Stock Purchase 7.74% $50,018 $9.04 5,533 77,018 06 Mar 2026 Direct
Gerard J. Michel DCTH Common Stock Purchase 3.39% $100,309 $8.96 11,200 342,034 02 Mar 2026 Direct
David L. Hoffman DCTH Restricted Stock Units Award 28,250 28,250 17 Feb 2026 Direct
David L. Hoffman DCTH Stock Option (Right to Buy) Award 56,500 56,500 17 Feb 2026 Direct
Kevin Muir DCTH Restricted Stock Units Award 28,250 28,250 17 Feb 2026 Direct
Kevin Muir DCTH Stock Option (Right to Buy) Award 56,500 56,500 17 Feb 2026 Direct
Sandra Pennell DCTH Restricted Stock Units Award 28,250 28,250 17 Feb 2026 Direct
Sandra Pennell DCTH Stock Option (Right to Buy) Award 56,500 56,500 17 Feb 2026 Direct
Vojo Vukovic DCTH Restricted Stock Units Award 28,250 28,250 17 Feb 2026 Direct
Vojo Vukovic DCTH Stock Option (Right to Buy) Award 56,500 56,500 17 Feb 2026 Direct
Martha S. Rook DCTH Restricted Stock Units Award 28,250 28,250 17 Feb 2026 Direct
Martha S. Rook DCTH Stock Option (Right to Buy) Award 56,500 56,500 17 Feb 2026 Direct
Gerard J. Michel DCTH Restricted Stock Units Award 97,500 97,500 17 Feb 2026 Direct
Gerard J. Michel DCTH Stock Option (Right to Buy) Award 195,000 195,000 17 Feb 2026 Direct
John Richard Sylvester DCTH Common Stock Purchase 41.6% $38,992 $8.89 4,386 14,936 21 Nov 2025 Direct
Gerard J. Michel DCTH Common Stock Purchase 3.6% $98,049 $8.53 11,500 330,834 11 Nov 2025 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .